YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666

  • J Antibiot (Tokyo). 2003 Apr;56(4):358-63. doi: 10.7164/antibiotics.56.358.
Masatoshi Taniguchi  1 ,  Koji Nagai ,  Nakako Arao ,  Tomihisa Kawasaki ,  Tetsu Saito ,  Yumiko Moritani ,  Jun Takasaki ,  Kazumi Hayashi ,  Shigeo Fujita ,  Ken-ichi Suzuki ,  Shin-ichi Tsukamoto
Affiliations
  • 1. Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. [email protected]
PMID: 12817809 DOI: 10.7164/antibiotics.56.358
Abstract

A novel platelet aggregation inhibitor, YM-254890, was isolated from the culture broth of strain QS3666. This strain was isolated from a soil sample collected at Okutama, Tokyo, Japan, and was identified as Chromobacterium sp. by morphological and physiological criteria. YM-254890 was purified from the culture supernatant by solvent extraction, ODS and silica gel flash chromatography, followed by preparative HPLC. YM-254890 inhibited ADP-induced platelet aggregation in human platelet-rich plasma with an IC50 value below 0.6 microM by blocking the P2Y1 receptor-signal transduction pathway.

Products